Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis

This study modelled the cost-effectiveness of 11 oral antipsychotics for relapse prevention among patients with remitted schizophrenia in Singapore. A network meta-analysis determined the relative efficacy and tolerability of 11 oral antipsychotics (amisulpride, aripiprazole, chlorpromazine, haloperidol, olanzapine, paliperidone, quetiapine, risperidone, sulpiride, trifluoperazine and ziprasidone). The clinical estimates were applied in a Markov model to estimate lifetime costs and quality-adjusted life-years gained. Quality-of-life data were obtained from published literature. Resource utilization and cost data were retrieved from local hospital databases. The annual direct cost of healthcare services for a patient experiencing a relapse episode was three-fold that of a patient not in relapse of schizophrenia. The most favourable pharmacological treatment for relapse prevention was olanzapine with an annual probability of relapse of 0.24 (0.13–0.38) with placebo as a reference of 0.75 (0.73–0.78). Olanzapine emerged as the dominant treatment with the highest quality-adjusted life-years gained and lowest lifetime costs. Ziprasidone, aripiprazole and paliperidone incurred higher lifetime costs compared with no treatment. Probability and cost of relapse were key drivers of cost-effectiveness in sensitivity analyses. The data can help prescribers in choosing appropriate treatment and payers in allocating resources for the clinical management of this serious psychiatric disorder.

[1]  A. Vita,et al.  Schizophrenia , 2016, The Lancet.

[2]  C. Correll,et al.  Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs , 2015, International clinical psychopharmacology.

[3]  R. Baldessarini,et al.  Critical issues on the use of network meta-analysis in psychiatry. , 2014, Harvard review of psychiatry.

[4]  C. G. Berardo,et al.  Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia , 2014, Expert review of pharmacoeconomics & outcomes research.

[5]  P. Rothwell,et al.  Quality of life after TIA and stroke , 2013, Neurology.

[6]  S. Kang,et al.  The Prevalence of Metabolic Syndrome in Schizophrenic Patients Using Antipsychotics , 2013, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[7]  H. Meltzer.  Update on typical and atypical antipsychotic drugs. , 2013, Annual review of medicine.

[8]  L. Hartling,et al.  Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications , 2012, Annals of Internal Medicine.

[9]  John M. Davis,et al.  Maintenance treatment with antipsychotic drugs for schizophrenia. , 2012, The Cochrane database of systematic reviews.

[10]  I. Oyagüez,et al.  Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses , 2012, Health Economics Review.

[11]  C. Correli.  RELAPSE PREVENTION IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF SECOND-GENERATION ANTIPSYCHOTICS VERSUS FIRST-GENERATION ANTIPSYCHOTICS , 2012, Schizophrenia Research.

[12]  T. Kishimoto,et al.  Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics , 2011, Molecular Psychiatry.

[13]  S. Osborne,et al.  Hospital treatment and management in relapse of schizophrenia in the UK: associated costs , 2011 .

[14]  H. Möller,et al.  Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) , 2009, European Psychiatry.

[15]  J. McGrath,et al.  Schizophrenia: a concise overview of incidence, prevalence, and mortality. , 2008, Epidemiologic reviews.

[16]  E. Rüther,et al.  A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany , 2006, The European Journal of Health Economics.

[17]  P. Mohr,et al.  Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores , 2004, Schizophrenia Research.

[18]  W. Fleischhacker,et al.  Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. , 2004, The Journal of clinical psychiatry.

[19]  M. Knapp,et al.  Relapse in schizophrenia: costs, clinical outcomes and quality of life , 2004, British Journal of Psychiatry.

[20]  Alastair Gray,et al.  Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62) , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[21]  J. Sachs.  Macroeconomics and health: investing in health for economic development , 2002 .

[22]  M. Knapp,et al.  Depot antipsychotic preparations in schizophrenia: the state of the economic evidence , 2002, International clinical psychopharmacology.

[23]  R. J. Wyatt,et al.  An economic evaluation of schizophrenia-1991 , 1995, Social Psychiatry and Psychiatric Epidemiology.

[24]  P. Janicak.  Principles and Practice of Psychopharmacotherapy , 1993 .

[25]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[26]  K. Kuntz,et al.  Economic Evaluation Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia , 2014 .

[27]  G. L’italien,et al.  Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK . , 2008, Current medical research and opinion.

[28]  M. Knapp,et al.  The global costs of schizophrenia. , 2004, Schizophrenia bulletin.

[29]  K. Rajagopalan,et al.  Clinicoeconomics and Outcomes Research Dovepress Long-term Cost-effectiveness of Atypical Antipsychotics in the Treatment of Adults with Schizophrenia in the Us , 2022 .

[30]  R. Conley,et al.  Cost Effectiveness and Resource Allocation Cost-effectiveness Model Comparing Olanzapine and Other Oral Atypical Antipsychotics in the Treatment of Schizophrenia in the United States , 2022 .

[31]  Jan Scott,et al.  Patient Related Outcome Measures Dovepress Nonadherence with Antipsychotic Medication in Schizophrenia: Challenges and Management Strategies , 2022 .